Background photo of air particle

OUR STORY

Committed to Helping People With PAH

TYVASO is produced by United Therapeutics Corporation, a biotechnology company founded by Martine and Bina Rothblatt in 1996 after their daughter was diagnosed with pulmonary arterial hypertension (PAH). United Therapeutics was born from a very personal and passionate desire to develop medicines that could help their daughter and others suffering from this rare disease.

Portrait of smiling woman on picnic with her kidsPortrait of smiling woman on picnic with her kids
bubbles for design
quotes icon

We are committed to helping people affected by PAH.

Martine Rothblatt

Chairperson and CEO,
United Therapeutics Corporation

A Personal Note From Our Founder

When our daughter was diagnosed with PAH, almost no treatment options were available. That’s why we decided to form United Therapeutics (UT) and dedicate ourselves to creating treatments for PAH.

Soon after we started that journey, our family spoke with others in similar situations and found there were limited support options available for people impacted by PAH. That’s when we realized UT could be doing more than creating new treatments.

We want to empower people throughout their PAH journeys—which is why support is such an integral part of our treatments. We are committed to helping people affected by PAH, until there is a cure.

Martine Rothblatt, PhD
Chairperson and CEO
United Therapeutics Corporation

How Can TYVASO Help Me?

TYVASO may help you do more in your day and do what matters most.

You May Have Side Effects

Talk to your healthcare provider and click below to learn more about potential side effects.

NOW APPROVED—
TYVASO DPI FITS IN THE PALM OF YOUR HAND

Ask your healthcare provider about the
Dry Powder Inhaler (DPI) option now approved for TYVASO®.

bubbles pattern
hand holding dpi devicebubbles pattern

See how simple TYVASO DPI is to use.

bubbles pattern